Bellerophon Therapeutics Inc. (BLPH)’s Financial Results Comparing With Kala Pharmaceuticals Inc. (NASDAQ:KALA)

This is therefore a comparing of the risk, analyst recommendations, profitability, institutional ownership, dividends, earnings and valuation in Bellerophon Therapeutics Inc. (NASDAQ:BLPH) and Kala Pharmaceuticals Inc. (NASDAQ:KALA). The two are both Biotechnology companies that compete with one another.

Valuation & Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bellerophon Therapeutics Inc. N/A 0.00 2.08M 0.01 51.95
Kala Pharmaceuticals Inc. 1.39M 120.52 80.83M -2.45 0.00

Demonstrates Bellerophon Therapeutics Inc. and Kala Pharmaceuticals Inc. earnings per share, gross revenue and valuation.

Profitability

Table 2 shows us Bellerophon Therapeutics Inc. and Kala Pharmaceuticals Inc.’s return on equity, return on assets and net margins.

Net Margins Return on Equity Return on Assets
Bellerophon Therapeutics Inc. 0.00% 0% -75.9%
Kala Pharmaceuticals Inc. -5,815.11% -104.2% -54.1%

Liquidity

Bellerophon Therapeutics Inc.’s Current Ratio is 2.3 while its Quick Ratio is 2.3. On the competitive side is, Kala Pharmaceuticals Inc. which has a 10.3 Current Ratio and a 9.9 Quick Ratio. Kala Pharmaceuticals Inc. is better positioned to pay off short and long-term obligations compared to Bellerophon Therapeutics Inc.

Analyst Recommendations

Bellerophon Therapeutics Inc. and Kala Pharmaceuticals Inc. Recommendations and Ratings are available in the next table.

Sell Ratings Hold Ratings Buy Ratings Rating Score
Bellerophon Therapeutics Inc. 0 0 1 3.00
Kala Pharmaceuticals Inc. 0 0 1 3.00

Bellerophon Therapeutics Inc. has a consensus target price of $3, and a 375.59% upside potential. Kala Pharmaceuticals Inc. on the other hand boasts of a $15 consensus target price and a 204.26% potential upside. Based on the data shown earlier, Bellerophon Therapeutics Inc. is looking more favorable than Kala Pharmaceuticals Inc., analysts view.

Insider and Institutional Ownership

Bellerophon Therapeutics Inc. and Kala Pharmaceuticals Inc. has shares held by institutional investors as follows: 47.6% and 81.6%. Insiders held 6% of Bellerophon Therapeutics Inc. shares. Competitively, Kala Pharmaceuticals Inc. has 4.25% of it’s share held by insiders.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Bellerophon Therapeutics Inc. 3.84% 4.71% -0.79% -36.28% -69.58% -15.72%
Kala Pharmaceuticals Inc. -16.34% -25.94% -14.29% -17.5% -65.66% 21.47%

For the past year Bellerophon Therapeutics Inc. had bearish trend while Kala Pharmaceuticals Inc. had bullish trend.

Summary

Bellerophon Therapeutics Inc. beats Kala Pharmaceuticals Inc. on 6 of the 11 factors.

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products at the intersection of drugs and devices that address unmet medical needs in the treatment of cardiopulmonary diseases. Its product candidates are INOpulse, a pulsatile nitric oxide delivery device, which is in Phase III clinical trials for the treatment of pulmonary arterial hypertension; and in Phase II clinical trials to treat pulmonary hypertension associated with chronic obstructive pulmonary diseases and pulmonary hypertension associated with idiopathic pulmonary fibrosis. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.

Kala Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies using its proprietary nanoparticle-based Mucus Penetrating Particles technology. The companyÂ’s product candidates include KPI-121 1.0%, which has completed Phase 3 clinical trials for the treatment of inflammation and pain following ocular surgery; and KPI-121 0.25% that is in Phase 3 clinical trials for the temporary relief of the signs and symptoms of dry eye disease. It also develops KPI-285, a receptor kinase inhibitor, which is in preclinical studies for the treatment of various retinal diseases. The company was formerly known as Hanes Newco, Inc. and changed its name to Kala Pharmaceuticals, Inc. in December 2009. Kala Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.